Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a ...

Vertex Pharmaceuticals and CRISPR Therapeutics' therapy for beta thalassemia and sickle cell disease is awaiting a regulatory decision in the U.S. and Europe, but the cystric fibrosis drug maker is ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

UTime Limited (Nasdaq: WTO), a global technology company engaged in the design and development of mobile devices today announced a major commercial breakthrough. UTime’s Hong Kong subsidiary, UTime ...

UTime (WTO) announced its Hong Kong subsidiary, UTime Technology, has officially signed a smart health device procurement ...